ICH Q7 clause 18: Specific guidance for APIs manufactured by cell culture/fermentation

Section 18 supplements the earlier sections for biotech and fermentation processes — it does not replace them. All other applicable GMP sections of this guide still apply in full to APIs manufactured by cell culture or fermentation. The section covers both classical fermentation processes for producing small molecules and modern biotechnology processes using recombinant or non-recombinant organisms for producing proteins, polypeptides, and other biological entities. The GMP principles are similar across these process types though specific controls differ based on the biological nature of the manufacturing system.

Biotech manufacturers must comply with BOTH the earlier sections AND Section 18. Section 18 doesn't replace earlier requirements; it adds biotech-specific requirements. Example: Section 6 (documentation) applies, plus Section 18's additional requirements for cell bank records. This ensures comprehensive GMP coverage for biotech while maintaining consistency with the rest of the guide.

Biotech processes have inherent biological variability — cells grow differently batch to batch, fermentation kinetics vary, impurity profiles shift. Controls to manage variability include: stringent CPP monitoring, cell line consistency (qualified cell banks), robust downstream purification, statistical process control, enhanced characterization (beyond what small-molecule APIs need). Despite variability, final product quality must be consistent through robust controls.

Biotech raw materials have unique quality concerns. Cell culture media components must be tested for growth promotion. Animal-derived components (serum, hydrolysates) have TSE/BSE risk requiring sourcing from safe regions. Sterile media must be tested for sterility or sterilized before use. Endotoxin limits apply to raw materials for parenteral products. Buffer components must be of appropriate grade.

Similar to the graduated GMP approach in Section 1.3 for small molecules, biotech and fermentation processes apply increasing levels of GMP control as processing progresses toward the final API. Cell expansion in early seed flasks operates under basic microbiological controls; production bioreactors operate under more stringent environmental and process monitoring; downstream purification steps operate under the highest level of controls approaching those for small-molecule APIs. The point at which full GMP controls are applied should be clearly defined and justified based on risk assessment. Controls at each process stage should be proportionate to the potential quality and safety impact on the final API.

Biotech and fermentation equipment must be designed to withstand repeated sterilization cycles, typically steam-in-place (SIP), or chemical sanitization without degradation. Materials of construction should be compatible with the sterilization method, with stainless steel 316L being standard for most wetted surfaces. Equipment design should incorporate smooth internal surfaces, minimised dead legs, drainable configurations, appropriate seal selection, and accessibility for inspection and cleaning. Sterilization validation is a critical regulatory focus area requiring documentation of cycle parameters and biological indicator results. All penetration points such as valves, sampling ports, and probe connections should be designed to prevent contamination ingress during operation.

Biotech and fermentation processes require monitoring of parameters not typically encountered in chemical synthesis. Key parameters include cell viability measured by exclusion dye methods, viable cell count, metabolite levels such as glucose consumption, lactate and ammonia production, product titer, and routine contamination checks. Physical parameters including pH, dissolved oxygen, temperature, and agitation rate should be captured continuously through automated control systems. Metabolic parameters are typically determined from periodic samples analysed at-line or off-line. Contamination checks using visual inspection, microscopic examination, and selective media cultures should be performed at defined intervals to prevent release of contaminated batches.

Downstream purification is the critical quality gate for biotech APIs and should effectively remove all process-related impurities including intact cells, cell debris, residual media components, host cell proteins (HCP), host cell DNA, endotoxins for APIs intended for parenteral drug products, and other product-related impurities such as aggregates and degradation products. Each purification step should be validated to demonstrate its clearance capability, with spiking studies or equivalent approaches used to establish clearance factors. The final purified API should be tested for residual levels of these impurities using validated analytical methods of appropriate sensitivity, and results should meet predefined acceptance specifications.

Cell banks are the foundation of biotech manufacturing processes and their loss or contamination can halt production entirely. Access controls should include physical locks or electronic key card systems, documented personnel authorisation lists, entry and exit logs, and where appropriate, camera surveillance. Cell bank storage areas typically have restricted access limited to a small number of specifically trained and authorised personnel. Each vial withdrawal should be treated as a controlled transaction with documentation recording the identity of the person, date, vial identification number, cell line identity, intended use, and updated inventory count.

Cell banks should be stored at ultra-low temperatures, typically in liquid nitrogen vapor phase at approximately minus 196 degrees Celsius, or in mechanical freezers at minus 80 degrees Celsius for shorter-term working cell bank storage. Vapor phase storage is preferred over liquid phase to prevent cross-contamination between vials. Storage systems should include continuous liquid nitrogen level monitoring, temperature data logging with defined alarm limits, automatic nitrogen replenishment, and backup power supply. Critical master and working cell banks should be stored at geographically separate backup locations to prevent total loss from a single catastrophic event such as equipment failure, fire, or prolonged power outage.

Cell bank records create the audit trail for one of the most critical manufacturing assets in biotechnology. Required record content should include vial withdrawal details covering date, specific vial identification number, quantity, identity of the person withdrawing, recipient, and intended use. Storage condition records should document continuous temperature monitoring data, liquid nitrogen levels, any alarm events, and excursion investigations. Cell bank qualification and characterisation records, along with ongoing stability testing results, should be maintained for the full lifecycle of the product. These records are typically retained for the life of the marketed product plus additional years per regulatory requirements.

Cell banks may change over time due to loss of viability during extended storage, genetic drift, contamination from storage conditions, or clonal evolution. Periodic monitoring should be performed to detect these changes before they affect production. Typical monitoring includes identity testing using STR profiling for mammalian cells or molecular methods for microorganisms, viability assessment after thawing, productivity verification through limited-scale culture, and contamination testing for bacteria, fungi, and mycoplasma. Monitoring frequency should be risk-based, with critical master cell banks monitored more frequently. Results should be compared against the original characterisation data to confirm that no significant changes have occurred that could affect product quality.

Adventitious agent testing is a critical safety requirement for biotech cell banks. The characterisation programme should include testing for mycoplasma using PCR and/or culture methods, bacterial and fungal contamination via sterility testing, viral contamination using in vitro cell-based assays and where appropriate in vivo assays, and species-specific pathogens relevant to the cell line origin. For master cell banks intended for production of APIs used in injectable drug products, extensive viral characterisation is required per ICH Q5A, including specific tests for retroviruses, retrovirus-like particles, adventitious viruses, and viruses known to be associated with the species of origin of the cell substrate.

Contamination during cell culture or fermentation is catastrophic and typically results in total batch loss. Controls during aseptic additions should include sterile filtration of liquid media and buffers through validated 0.2 micrometre filters, use of autoclaved solid components and sterile containers, aseptic connection techniques such as aseptic tube welding or validated sterile connector fittings, and single-use disposable assemblies for critical transfer paths. Environmental controls in the operating area should include appropriate air classification and monitoring. Aseptic techniques and procedures should be validated through media fill simulations or equivalent qualification studies performed at defined intervals.

Biotech CPPs directly affect cell behavior and product quality. Temperature affects enzyme activity and product formation. pH affects cell viability and metabolism. Dissolved oxygen (DO) supports cell respiration. Agitation ensures mixing and mass transfer. Nutrient levels drive growth and production. All of these must be continuously monitored (modern bioreactors have probes for all), controlled via automated systems, and kept within validated ranges. Excursions trigger investigation.

Biotech equipment cleaning is more complex than chemical manufacturing — residual cells, proteins, and biological materials can harbor contamination and affect subsequent batches. CIP systems use chemical cleaning solutions in automated cycles. SIP systems use steam for sterilization. Both should be validated with worst-case conditions. Residues should be measured using appropriate analytical methods (protein assays, nucleic acid tests). Sterilization effectiveness is measured via biological indicators.

Non-sterile media introduced into cell culture or fermentation systems will cause contamination and batch loss. Sterilisation methods should be selected based on the thermal sensitivity of the media components: autoclaving is appropriate for heat-stable components and aqueous solutions, while filtration through validated 0.2 micrometre filters should be used for heat-sensitive components including many growth factors and vitamins. Filter integrity should be verified both before and after use by bubble point testing or equivalent methods. Sterilised media should be stored in validated sterile containers under controlled conditions and used within defined time limits supported by hold-time studies to prevent microbial recontamination prior to use in production.

Contamination detection methods depend on potential contaminants. For bacterial contamination: turbidity in clear media, change in growth patterns, selective media cultures, gram staining, molecular methods (PCR). For fungal contamination: visual observation, selective media. For mycoplasma: specialized PCR or culture. Detection should occur at key process points: post-inoculation, during fermentation, pre-harvest. Any contamination requires batch rejection or investigation for specific organism impact.

Contamination investigations in biotech manufacturing should be treated as high-priority events given the potential impact on patient safety and batch loss. The investigation scope should include identification of the contaminating organism through speciation, determination of the source by evaluating raw materials, equipment, operator practices, and environmental monitoring data, assessment of the impact on the affected batch which is typically rejected, and assessment of whether other batches manufactured with shared equipment or materials may also be affected. Root cause analysis should lead to corrective and preventive actions, and contamination events should be trended over time to reveal systemic issues such as recurring contamination from specific sources, equipment, or operations.

Equipment dedication reduces the complexity of cross-contamination control and the burden of cleaning validation. Dedicated fermenters and bioreactors assigned to specific cell lines or products eliminate the risk of biological cross-contamination between different organisms and reduce the required scope of cleaning validation. Where multi-product use of equipment is necessary, cleaning validation should be extensive and should specifically address the removal of residual cells, proteins, host cell DNA, and any biological markers that could indicate carry-over between campaigns. The decision to dedicate or share equipment should be documented with a risk-based rationale. Equipment dedication is typically more common for commercial production; development operations may use shared equipment with appropriate validated cleaning and changeover controls.

Contamination event records provide essential data for continuous improvement and regulatory compliance. Detailed records should support trend analysis to identify whether certain production areas, equipment, operations, or time periods are more prone to contamination events. The records should enable root cause analysis for recurring contamination patterns and facilitate regulatory reporting where required. Records should be maintained in a centralised, searchable system to support periodic trending. Annual or semi-annual reviews of contamination event records should be conducted by the quality unit to identify systemic issues and evaluate the effectiveness of corrective actions previously implemented.

Cleaning validation for shared biotech equipment is more complex than for chemical manufacturing because biological residues including viable cells, host cell proteins, host cell DNA, and product-specific residues must all be demonstrated to be effectively removed. Analytical tests should include total protein assays, product-specific immunoassays such as ELISA, nucleic acid quantification for host cell DNA, viable organism testing, and cleaning agent residue testing. Worst-case product identification for the validation programme should consider cell line characteristics including hardiness and adhesion properties, product stickiness and thermal stability, and relative cleaning difficulty. The validation programme should cover all product pair combinations that may share the equipment.

Harvesting is the first downstream processing step, transitioning from cell culture or fermentation to purification. For secreted products, the objective is to remove cells and cell debris while retaining the product in the clarified supernatant. For intracellular products, cells are concentrated and then lysed to release the product. Harvesting methods should be sufficiently gentle to preserve product integrity, as proteins and other biological molecules can denature or aggregate under excessive shear stress. Equipment commonly used includes disc-stack centrifuges, depth filters, tangential flow filtration systems, and settling tanks. Process time during harvesting is often critical to product quality, as product stability may decrease once removed from controlled culture conditions.

Harvest validation should demonstrate that the process reliably produces intermediate material of acceptable quality for downstream purification. Validation parameters depend on the specific harvesting method employed: for centrifugation these include relative centrifugal force, spin time, and temperature; for tangential flow filtration the key parameters are flux rate, transmembrane pressure, and filter membrane area; for depth filtration the parameters include filter area per unit volume processed and differential pressure across the filter. Product recovery is a key performance metric and low recovery should be investigated for product losses. Post-harvest product quality attributes including purity, aggregate levels, and biological activity should be verified as part of the validation programme.

Biotech purification typically employs multiple orthogonal steps: clarification to remove cells and debris, capture chromatography for initial product isolation often using affinity methods such as Protein A for monoclonal antibodies, intermediate purification using ion exchange or hydrophobic interaction chromatography, and a polishing step for final impurity removal using size exclusion or mixed-mode chromatography. Each step has specific objectives targeting different impurity classes and the orthogonal nature of the chromatographic mechanisms ensures comprehensive impurity clearance across the purification train. Each step's clearance capacity for critical impurities including host cell proteins, host cell DNA, and product-related variants should be validated through spiking studies or characterisation of process intermediates.

Purification validation should cover all process parameters that affect product quality and impurity removal. For chromatography steps the validated parameters should include loading capacity and conditions, wash and elution buffer compositions and volumes, pH and conductivity, temperature, flow rates, and column packing integrity. Resin lifetime studies should establish the maximum number of use cycles before resin replacement is required. Column cleaning validation should demonstrate that product and impurity carry-over does not accumulate across cycles. Column storage conditions between uses should be validated to prevent microbial contamination and resin degradation. The validation programme should address both typical operating conditions and worst-case scenarios.

Biotech process intermediates can be inherently unstable during hold periods, with risks including protein denaturation, aggregate formation, chemical modification, and microbial contamination growth in nutrient-rich solutions. Hold time validation should demonstrate that the intermediate remains suitable for downstream processing throughout the maximum anticipated hold period under the specified conditions. Typical hold conditions include refrigerated storage at 2 to 8 degrees Celsius or frozen at minus 20 or minus 80 degrees Celsius, in sterile or low-bioburden containers, with controlled headspace. Validation studies should include product stability testing covering potency and purity, microbial growth potential assessment, container compatibility evaluation, and monitoring of pH and other relevant solution properties.

Viral clearance is critical for biotech APIs from mammalian or insect cell lines (which can harbor viruses) intended for parenteral use. ICH Q5A provides detailed guidance on viral safety evaluation. Typical viral clearance steps: low pH inactivation, solvent/detergent treatment, nanofiltration, chromatography (ion exchange provides some clearance). Orthogonal mechanisms ensure different virus types are addressed. Validation uses spiking studies with model viruses.

Viral clearance effectiveness depends critically on maintaining process parameters within validated ranges. Low pH inactivation requires the product to be held at a specific pH value and for a defined minimum hold time at controlled temperature. Solvent/detergent treatment requires specific reagent concentrations and exposure duration. Nanofiltration requires controlled transmembrane pressure, flow rate, and validated filter integrity. Deviations outside the validated parameter ranges may compromise the viral clearance achieved and should be investigated for their impact on viral safety. Each viral clearance step should be monitored during routine production with all critical parameters recorded in the batch record and compared against the validated acceptance criteria.

Viral clearance steps lose their protective value if the product is recontaminated with virus after the clearance step has been performed. Controls to prevent recontamination should include physical separation of pre-clearance and post-clearance processing operations, dedication of equipment used in post-clearance steps to prevent contact with pre-clearance materials, controlled unidirectional personnel flow with gowning changes when moving from pre-clearance to post-clearance areas, and use of closed transfer systems between processing steps. Some facilities employ completely separate rooms or buildings for post-viral-clearance operations to provide maximum assurance against recontamination from biological material at earlier process stages.

The level of physical separation required for viral clearance operations should be determined through a documented risk assessment. In high-risk cases, complete facility separation may be required with pre-clearance operations in one building and post-clearance operations in another, with no shared personnel or equipment. More commonly, the same facility employs defined zones with controlled transitions, gowning changes, and unidirectional flow. Dedicated heating, ventilation, and air conditioning systems should be considered to prevent airborne cross-contamination between pre-clearance and post-clearance areas. The risk assessment should consider the viral load in pre-clearance material, the demonstrated effectiveness of the clearance steps, the criticality of downstream operations, and applicable regulatory expectations.